A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of this Phase I study is to access the safety and tolerability of Y150 at
different dose levels. It is hoped to find out the recommended dose for Phase II/III.